Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

ClinicalTrials.gov ID: NCT00978627

Public ClinicalTrials.gov record NCT00978627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST™: T1)

Study identification

NCT ID
NCT00978627
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
548 participants

Conditions and interventions

Interventions

  • insulin aspart Drug
  • insulin degludec/insulin aspart Drug
  • insulin detemir Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2009
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010
Last update posted
Mar 19, 2017

2009 – 2010

United States locations

U.S. sites
30
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Novo Nordisk Investigational Site La Mesa California 91942
Novo Nordisk Investigational Site Lancaster California 93534
Novo Nordisk Investigational Site Mission Hills California 91345
Novo Nordisk Investigational Site North Hollywood California 91606
Novo Nordisk Investigational Site Salinas California 93901
Novo Nordisk Investigational Site Valencia California 91355
Novo Nordisk Investigational Site Aurora Colorado 80045
Novo Nordisk Investigational Site Miami Florida 33156
Novo Nordisk Investigational Site Miami Florida 33169
Novo Nordisk Investigational Site Atlanta Georgia 30318
Novo Nordisk Investigational Site Lawrenceville Georgia 30046
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Honolulu Hawaii 96814
Novo Nordisk Investigational Site Chicago Illinois 60607
Novo Nordisk Investigational Site Shawnee Mission Kansas 66204
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Eagan Minnesota 55123
Novo Nordisk Investigational Site Minneapolis Minnesota 55416
Novo Nordisk Investigational Site City of Saint Peters Missouri 63376
Novo Nordisk Investigational Site Butte Montana 59701
Novo Nordisk Investigational Site Omaha Nebraska 68131
Novo Nordisk Investigational Site Henderson Nevada 89052-2649
Novo Nordisk Investigational Site Albany New York 12206
Novo Nordisk Investigational Site Northport New York 11768
Novo Nordisk Investigational Site Morehead City North Carolina 28557
Novo Nordisk Investigational Site Greer South Carolina 29651
Novo Nordisk Investigational Site Dallas Texas 75390-9302
Novo Nordisk Investigational Site San Antonio Texas 78215
Novo Nordisk Investigational Site San Antonio Texas 78240
Novo Nordisk Investigational Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00978627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2017 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00978627 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →